

Edgar Filing: BALCHEM CORP - Form 10-Q

BALCHEM CORP
Form 10-Q
May 08, 2009

FORM 10-Q

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

(Mark One) Quarterly Report Pursuant to Section 13 or 15(d) of
 the Securities Exchange Act of 1934
☒ |

For The Quarterly Period Ended March 31, 2009

or

Transition Report Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

For the transition period from _____ to _____

Commission File Number 1-13648

BALCHEM CORPORATION
(Exact name of registrant as specified in its charter)

Maryland

13-2578432

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer Identification Number)

P.O. Box 600 New Hampton, New York

10958

(Address of principal executive offices)

(Zip Code)

845-326-5600

Registrant's telephone number, including area code:

Indicate by a check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to filing requirements for the past 90 days.

Yes ☒ |

No ☐ |

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes ☐ |

No ☐ |

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ |

Accelerated filer ☒ |

Non-accelerated filer ☐ |

Smaller reporting company ☐ |

Edgar Filing: BALCHEM CORP - Form 10-Q

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 1, 2009 the registrant had 18,334,897 shares of its Common Stock, \$.06 2/3 par value, outstanding.

Part 1 - Financial Information

Item 1. Financial Statements

BALCHEM CORPORATION

Condensed Consolidated Balance Sheets

(Dollars in thousands, except per share data)

	Assets	March 31, 2009 (unaudited)	Deco
	-----	-----	---
Current assets:			
Cash and cash equivalents		\$ 18,553	\$
Accounts receivable, net		25,000	
Inventories		15,305	
Prepaid expenses		1,809	
Deferred income taxes		928	
Other current assets		701	
		-----	---
Total current assets		62,296	
Property, plant and equipment, net		41,394	
Goodwill		26,658	
Intangible assets with finite lives, net		29,038	
Other assets		55	
		-----	---
Total assets		\$ 159,441	\$
		=====	===
	Liabilities and Stockholders' Equity		

Current liabilities:			
Trade accounts payable		\$ 7,443	\$
Accrued expenses		5,548	
Accrued compensation and other benefits		2,468	
Dividends payable		--	
Income tax payable		5,188	
Current portion of long-term debt		1,415	
Revolver borrowings		1,915	
		-----	---
Total current liabilities		23,977	
Long-term debt		5,896	
Deferred income taxes		5,520	
Other long-term obligations		1,641	
		-----	---
Total liabilities		37,034	

Edgar Filing: BALCHEM CORP - Form 10-Q

Commitments and contingencies (note 12)

Stockholders' equity:

Common stock, \$.0667 par value. Authorized 25,000,000 shares; 18,333,884 shares issued and outstanding at March 31, 2009 and 18,249,347 shares issued and outstanding at December 31, 2008	828
Preferred stock, \$25 par value. Authorized 2,000,000 shares; none issued and outstanding	--
Additional paid-in capital	20,673
Retained earnings	100,980
Accumulated other comprehensive income	(74)
Total stockholders' equity	122,407

Total liabilities and stockholders' equity	\$ 159,441	\$
--	------------	----

See accompanying notes to condensed consolidated financial statements.

2

BALCHEM CORPORATION Condensed Consolidated Statements of Earnings (Dollars in thousands, except per share data) (unaudited)

	Three Months Ended March 31,	
	2009	2008
Net sales	\$ 52,986	\$ 56,861
Cost of sales	36,688	43,378
Gross margin	16,298	13,483
Operating expenses:		
Selling expenses	3,649	3,319
Research and development expenses	808	782
General and administrative expenses	2,531	1,978
	6,988	6,079
Earnings from operations	9,310	7,404
Other expenses (income):		
Interest income	(10)	(25)
Interest expense	74	323
Other, net	80	(85)

Edgar Filing: BALCHEM CORP - Form 10-Q

Earnings before income tax expense	9,166	7,191
Income tax expense	3,068	2,550
	-----	-----
Net earnings	\$ 6,098	\$ 4,641
	=====	=====
Net earnings per common share - basic	\$ 0.34	\$ 0.26
	=====	=====
Net earnings per common share - diluted	\$ 0.32	\$ 0.25
	=====	=====

See accompanying notes to condensed consolidated financial statements.

3

BALCHEM CORPORATION Condensed Consolidated Statements of Cash Flows (Dollars in thousands) (unaudited)

	Three Months March 31, 2009	
	-----	-----
Cash flows from operating activities:		
Net earnings	\$ 6,098	\$
Adjustments to reconcile net earnings to net cash provided by operating activities:		
Depreciation and amortization	2,001	
Reserve for doubtful accounts	373	
Shares issued under employee benefit plans	133	
Deferred income taxes	(750)	
Foreign currency transaction (gain) loss	44	
Stock compensation expense	758	
Changes in assets and liabilities:		
Accounts receivable	4,420	
Inventories	1,203	
Prepaid expenses and other current assets	1,732	
Income taxes	3,230	
Customer deposits and other deferred revenue	(5)	
Accounts payable and accrued expenses	(775)	
Other	40	
	-----	-----
Net cash provided by operating activities	18,502	
	-----	-----
Cash flows from investing activities:		
Capital expenditures	(594)	
Proceeds from sale of property, plant and equipment	3	
Acquisition of assets	(12)	
	-----	-----
Net cash used in investing activities	(603)	
	-----	-----

Edgar Filing: BALCHEM CORP - Form 10-Q

Cash flows from financing activities:

Revolver borrowings	--
Revolver repayments	--
Principal payments on long-term debt	(1,700)
Proceeds from stock options exercised	701
Excess tax benefits from stock compensation	278
Dividends paid	(2,007)

Net cash used in financing activities	(2,728)
---------------------------------------	---------

Effect of exchange rate changes on cash	(40)
---	------

Increase in cash and cash equivalents	15,131
---------------------------------------	--------

Cash and cash equivalents beginning of period	3,422
---	-------

Cash and cash equivalents end of period	\$ 18,553
---	-----------

See accompanying notes to condensed consolidated financial statements.

4

BALCHEM CORPORATION Condensed Consolidated Statements of Comprehensive Income (Dollars in thousands) (unaudited)

	Three Months Ended March 31,	
	2009	2008
Net earnings	\$ 6,098	\$ 4,641
Other comprehensive income, net of tax:		
Unfunded postretirement benefit plan	(3)	(5)
Other	(63)	9
Comprehensive income	\$ 6,032	\$ 4,645

See accompanying notes to condensed consolidated financial statements.

5

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(All dollar amounts in thousands, except per share data)

Edgar Filing: BALCHEM CORP - Form 10-Q

NOTE 1 - CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

The condensed consolidated financial statements presented herein have been prepared by the Company in accordance with the accounting policies described in its December 31, 2008 consolidated financial statements, and should be read in conjunction with the consolidated financial statements and notes, which appear in the Annual Report on Form 10-K for the year ended December 31, 2008. References in this report to the "Company" mean either Balchem Corporation or Balchem Corporation and its subsidiaries, including BCP Ingredients, Inc., Balchem Minerals Corporation, and Balchem B.V., on a consolidated basis, as the context requires.

In the opinion of management, the unaudited condensed consolidated financial statements furnished in this Form 10-Q include all adjustments necessary for a fair presentation of the financial position, results of operations and cash flows for the interim periods presented. All such adjustments are of a normal recurring nature. The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles governing interim financial statements and the instructions to Form 10-Q and Article 10 of Regulation S-X under the Securities Exchange Act of 1934 and therefore do not include some information and notes necessary to conform to annual reporting requirements. Certain prior year amounts have been reclassified to conform to current year presentation. The results of operations for the three months ended March 31, 2009 are not necessarily indicative of the operating results expected for the full year or any interim period.

NOTE 2 - STOCKHOLDERS' EQUITY

STOCK-BASED COMPENSATION

The Company records stock-based compensation in accordance with the provisions of Statement of Financial Accounting Standards ("SFAS") No. 123 (revised 2004), "Share Based Payment" ("SFAS 123R"). The Company's results for the three months ended March 31, 2009 and 2008 reflected the following stock-based compensation cost, and such compensation cost had the following effects on net earnings and basic and diluted earnings per share:

	Three Months Ended March 31, 2009	Three Months Ended March 31, 2008
Cost of sales	\$ 90	\$ 66
Operating expenses	668	556
Net earnings	(478)	(412)
Basic earnings per common share	(0.03)	(0.02)
Diluted earnings per common share	\$ (0.03)	\$ (0.02)

As required by SFAS 123R, the Company has made an estimate of expected forfeitures based on its historical experience and is recognizing compensation cost only for those stock-based compensation awards expected to vest.

The Company's stock incentive plans allow for the granting of restricted stock awards and options to purchase common stock. Both incentive stock options and

Edgar Filing: BALCHEM CORP - Form 10-Q

nonqualified stock options can be awarded under the plans. No option will be exercisable for longer than ten years after the date of grant. The Company has approved and reserved a number of shares to be issued upon exercise of the outstanding options that is adequate to cover all exercises. As of March 31, 2009, the plans had 3,664,350 shares available for future awards. Compensation expense for stock options and restricted stock awards is recognized on a straight-line basis over the vesting period, generally three years for stock options, four years for employee restricted stock awards, and four to seven years for non-employee director restricted stock awards. Certain awards provide for accelerated vesting if there is a change in control (as defined in the plans) or other qualifying events.

Option activity for the three months ended March 31, 2009 and 2008 is summarized below:

For the three months ended March 31, 2009	Shares (000s)	Weighted Average Exercise Price	Aggregate Intrinsic Value (\$000s)	Weighted Average Remaining Contractual Term
Outstanding as of December 31, 2008	2,396	\$ 13.82	\$ 26,873	
Granted	--	--		
Exercised	(79)	8.90		
Expired	--	--		
Forfeited	(3)	19.54		
Outstanding as of March 31, 2009	2,314	\$ 13.97	\$ 26,037	6.5
Exercisable as of March 31, 2009	1,675	\$ 10.79	\$ 24,020	5.5

7

For the three months ended March 31, 2008	Shares (000s)	Weighted Average Exercise Price	Aggregate Intrinsic Value (\$000s)	Weighted Average Remaining Contractual Term
Outstanding as of December 31, 2007	1,944	\$ 10.66	\$ 22,786	
Granted	307	20.41		
Exercised	(47)	8.78		
Expired	--	--		
Forfeited	--	--		
Outstanding as of March 31, 2008	2,204	\$ 12.05	\$ 23,947	6.9
Exercisable as of March 31, 2008	1,456	\$ 9.12	\$ 20,088	6.0

SFAS 123R requires companies to measure the cost of employee services received in exchange for an award of equity instruments based on the grant-date fair

Edgar Filing: BALCHEM CORP - Form 10-Q

value of the award. The fair value of each option grant is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions for the three months ended March 31, 2008: dividend yield of 0.6%, expected volatility of 40%, risk-free interest rate of 2.8%, and expected life of 3.5. There were no options granted during the three months ended March 31, 2009.

The Company used a projected expected life for each award granted based on historical experience of employees' exercise behavior. Expected volatility is based on the Company's historical volatility levels. Dividend yields are based on the Company's historical dividend yields. Risk-free interest rates are based on the implied yields currently available on U.S. Treasury zero coupon issues with a remaining term equal to the expected life.

Other information pertaining to option activity during the three months ended March 31, 2009 and 2008 was as follows:

	Three Months Ended March 31,	
	2009	2008
Weighted-average fair value of options granted	\$ N/A	\$ 6.38
Total intrinsic value of stock options exercised (\$000s)	\$ 1,027	\$ 610

8

Non-vested restricted stock activity for the three months ended March 31, 2009 and 2008 is summarized below:

Three months ended March 31, 2009		Weighted Average Grant Date Fair Value
	Shares (000s)	
Non-vested balance as of December 31, 2008	232	\$ 20.08
Granted	--	--
Vested	--	--
Forfeited	--	--
Non-vested balance as of March 31, 2009	232	\$ 20.08

Three months ended March 31, 2008		Weighted Average Grant Date Fair Value
	Shares (000s)	
Non-vested balance as of December 31, 2007	118	\$ 16.49
Granted	73	20.77
Vested	--	--
Forfeited	--	--
Non-vested balance as of March 31, 2008	191	\$ 18.10

Edgar Filing: BALCHEM CORP - Form 10-Q

As of March 31, 2009 and 2008, there was \$6,725 and \$5,347, respectively, of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the plans. As of March 31, 2009, the unrecognized compensation cost is expected to be recognized over a weighted-average period of 2 years. The Company estimates that share-based compensation expense for the year ended December 31, 2009 will be approximately \$3,000.

REPURCHASE OF COMMON STOCK

The Company has a stock repurchase program that was approved by the board of directors. The total authorization under this program is 2,508,692 shares. Since the inception of the program, a total of 1,307,867 shares have been purchased, none of which remained in treasury at March 31, 2009 or 2008. During the three months ended March 31, 2009, no additional shares have been purchased. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it advisable to do so based on its assessment of corporate cash flow, market conditions and other factors.

NOTE 3 - INVENTORIES

Inventories at March 31, 2009 and December 31, 2008 consisted of the following:

	March 31, 2009	December 31, 2008
Raw materials	\$ 5,544	\$ 5,931
Work in progress	1,013	540
Finished goods	8,748	10,147
Total inventories	\$ 15,305	\$ 16,618

NOTE 4 - PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment at March 31, 2009 and December 31, 2008 are summarized as follows:

9

	March 31, 2009	December 31, 2008
Land	\$ 1,997	\$ 2,088
Building	15,247	15,426
Equipment	51,568	50,719
Construction in progress	1,995	2,654
	70,807	70,887
Less: accumulated depreciation	29,413	28,374
Net property, plant and equipment	\$ 41,394	\$ 42,513

Edgar Filing: BALCHEM CORP - Form 10-Q

NOTE 5 - INTANGIBLE ASSETS

The Company had goodwill in the amount of \$26,658 at March 31, 2009 and December 31, 2008, subject to the provisions of SFAS Nos. 141 and 142.

As of March 31, 2009 and December 31, 2008, the Company had identifiable intangible assets with finite lives with a gross carrying value of approximately \$37,388 and \$37,431, respectively, less accumulated amortization of \$8,350 and \$7,438, respectively.

Identifiable intangible assets with finite lives at March 31, 2009 and December 31, 2008 are summarized as follows:

	Amortization Period (in years)	Gross Carrying Amount at 3/31/09	Accumulated Amortization at 3/31/09	Gross Carrying Amount at 12/31/08	Accumulated Amortization at 12/31/08
Customer lists	10	\$34,150	\$ 7,449	\$34,150	\$ 6,595
Regulatory re-registration costs	10	85	5	85	3
Patents & trade secrets	15-17	1,682	431	1,673	406
Trademarks & trade names	17	908	211	904	198
Other	5-10	563	254	619	236
		\$37,388	\$ 8,350	\$37,431	\$7,438

Amortization of identifiable intangible assets was \$912 for the first three months of 2009. Assuming no change in the gross carrying value of identifiable intangible assets, the estimated amortization expense for the remainder of 2009 is \$2,735 and approximately \$3,600 per annum for 2010 through 2014. At March 31, 2009, there were no identifiable intangible assets with indefinite useful lives as defined by SFAS No. 142. Identifiable intangible assets are reflected in "Intangible assets with finite lives, net" in the Company's condensed consolidated balance sheets. There were no changes to the useful lives of intangible assets subject to amortization during the three months ended March 31, 2009.

10

NOTE 6 - NET EARNINGS PER SHARE

The following presents a reconciliation of the net earnings and shares used in calculating basic and diluted net earnings per share:

	Net Earnings (Numerator)	Number of Shares (Denominator)	Per Share Amount
Three months ended March 31, 2009			

Edgar Filing: BALCHEM CORP - Form 10-Q

Basic EPS - Net earnings and weighted average common shares outstanding	\$ 6,098	18,070,351	\$.34
---	----------	------------	-------

Effect of dilutive securities - stock options and restricted stock		959,012	

Diluted EPS - Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	\$ 6,098	19,029,363	\$.32
--	----------	------------	-------

	Net Earnings (Numerator)	Number of Shares (Denominator)	Per Share Amount
--	--------------------------------	--------------------------------------	---------------------

Basic EPS - Net earnings and weighted average common shares outstanding	\$ 4,641	17,901,739	\$.26
---	----------	------------	-------

Effect of dilutive securities - stock options and restricted stock		951,741	

Diluted EPS - Net earnings and weighted average common shares outstanding and effect of stock options and restricted stock	\$ 4,641	18,853,480	\$.25
--	----------	------------	-------

The Company had stock options covering 639,150 and 315,200 shares at March 31, 2009 and 2008, respectively, that could potentially dilute basic earnings per share in future periods that were not included in diluted earnings per share because their effect on the period presented was anti-dilutive.

NOTE 7 - INCOME TAXES

The Company adopted the provisions of FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes", or FIN 48, on January 1, 2007. FIN 48 clarifies whether or not to recognize assets or liabilities for tax positions taken that may be challenged by a tax authority. Upon adoption of FIN 48, the Company recognized approximately a \$291 decrease in its retained earnings balance. The charge before federal tax benefits was \$411. The Company includes interest expense or income as well as potential penalties on unrecognized tax positions as a component of income tax expense in the consolidated statements of earnings. The total amount of accrued interest and penalties related to uncertain tax positions at March 31, 2009 was approximately \$152 and is included in

other long-term obligations. All of the unrecognized tax benefits, if recognized in future periods, would impact the Company's effective tax rate. The Company files income tax returns in the U.S. and in various states and foreign countries. As of March 31, 2009, in the major jurisdictions where the Company operates, it is generally no longer subject to income tax examinations by tax authorities for years before 2005. There was not a significant change in the liabilities for unrecognized tax benefits during the three months ended March 31, 2009.

Edgar Filing: BALCHEM CORP - Form 10-Q

NOTE 8 - SEGMENT INFORMATION

The Company's reportable segments are strategic businesses that offer products and services to different markets. Presently, the Company has three segments: Specialty Products; Food, Pharma & Nutrition; and Animal Nutrition & Health.

Business Segment Net Sales:

	Three Months Ended March 31,	
	2009	2008
Specialty Products	\$ 8,794	\$ 8,450
Food, Pharma & Nutrition	8,304	9,289
Animal Nutrition & Health	35,888	39,122
Total	\$ 52,986	\$ 56,861

Business Segment Earnings Before Income Taxes:

	Three Months Ended March 31,	
	2009	2008
Specialty Products	\$ 3,387	\$ 2,598
Food, Pharma & Nutrition	959	1,528
Animal Nutrition & Health	4,964	3,278
Interest and other expense	(144)	(213)
Total	\$ 9,166	\$ 7,191

The following table summarizes domestic (U.S.) and foreign sales for the three months ended March 31, 2009 and March 31, 2008:

	Three Months Ended March 31,	
	2009	2008
Domestic	\$ 37,040	\$ 35,028
Foreign	15,946	21,833
Total	\$ 52,986	\$ 56,861

NOTE 9 - SUPPLEMENTAL CASH FLOW INFORMATION

Cash paid during the three months ended March 31, 2009 and 2008 for income taxes and interest is as follows:

Edgar Filing: BALCHEM CORP - Form 10-Q

	Three months ended March 31,	
	2009	2008
Income taxes	\$ 376	\$ 296
Interest	\$ 109	\$ 323

NOTE 10 - LONG-TERM DEBT AND CREDIT AGREEMENTS

On April 30, 2007, the Company, and its principal bank entered into a Loan Agreement (the "European Loan Agreement") providing for an unsecured term loan of (euro)7,500, translated to \$9,906 as of March 31, 2009 (the "European Term Loan"), the proceeds of which were used to fund the 2007 Akzo Nobel Acquisition (described in Note 5 of the Company's Form 10-K as of December 31, 2008) and initial working capital requirements. The European Term Loan is payable in equal monthly installments of principal, each equal to 1/84th of the principal of the European Term Loan, together with accrued interest, with remaining principal and interest payable at maturity. The European Term Loan has a maturity date of May 1, 2010 and is subject to a monthly interest rate equal to EURIBOR plus 1%. At March 31, 2009, this interest rate was 2.54%. At March 31, 2009, the European Term Loan had an outstanding balance of (euro)5,536, translated to \$7,312. The European Loan Agreement also provides for a short-term revolving credit facility of (euro)3,000, translated to \$3,962 as of March 31, 2009 (the "European Revolving Facility"). The European Revolving Facility has been renewed for a period of one year as of May 1, 2009. The current European Revolving Facility is subject to an amended monthly interest rate equal to EURIBOR plus 1.45%, and accrued interest is payable monthly. The Company has drawn down (euro)1,450, or \$1,915 as translated at March 31, 2009, of the European Revolving Facility as of March 31, 2009. Management believes that such facility will be renewed in the normal course of business.

On March 16, 2007, the Company and its principal bank entered into a Loan Agreement (the "Loan Agreement") providing for an unsecured term loan of \$29,000 (the "Term Loan"), the proceeds of which were used to fund the 2007 Chinook Acquisition (described in Note 5 of the Company's Form 10-K as of December 31, 2008). During the quarter ended March 31, 2009, the Company prepaid \$867, the remaining balance of the Term Loan. The Loan Agreement also provides for a short-term revolving credit facility of \$6,000 (the "Revolving Facility"). The Revolving Facility is subject to a monthly interest rate equal to LIBOR plus 1%, and accrued interest is payable monthly. No amounts are outstanding on the Revolving Facility as of the date hereof. The Revolving Facility has a maturity date of May 31, 2010. Management believes that such facility will be renewed in the normal course of business.

NOTE 11 - EMPLOYEE BENEFIT PLAN

The Company currently provides postretirement benefits in the form of a retirement medical plan under a collective bargaining agreement covering eligible retired employees of its Verona, Missouri facility.

Net periodic benefit cost for such retirement medical plan for the three months ended March 31, 2009 and March 31, 2008 was as follows:

Edgar Filing: BALCHEM CORP - Form 10-Q

Service cost	\$	8	\$	8
Interest cost		11		11
Expected return on plan assets		--		--
Amortization of transition obligation		--		--
Amortization of prior service cost		(5)		(4)
Amortization of gain		(1)		--
Net periodic benefit cost	\$	13	\$	15

The amount recorded on the Company's balance sheet as of March 31, 2009 for this obligation is \$833. The plan is unfunded and approved claims are paid from Company funds. Historical cash payments made under such plan approximated \$50 per year.

NOTE 12 - COMMITMENTS AND CONTINGENCIES

As part of the June 30, 2005 acquisition of certain assets relating to the encapsulation, agglomeration and granulation business of Loders Croklaan USA, LLC, the Company entered into a lease agreement with Loders under which the Company leases a portion of Loders' Channahon, Illinois facility where it principally conducted the manufacturing portion of the acquired business and utilized certain warehouse space. The initial term of the lease commenced in February, 2006 and runs through September 30, 2010, subject to earlier termination.

In February 2002, the Company entered into a ten (10) year lease which is cancelable in 2009 for approximately 20,000 square feet of office space. The office space is now serving as the Company's general offices and as a laboratory facility. The Company leases most of its vehicles, railcars and office equipment under non-cancelable operating leases, which primarily expire at various times through 2013. Rent expense charged to operations under such lease agreements for the three months ended March 31, 2009 and 2008 aggregated approximately \$286 and \$223, respectively. Aggregate future minimum rental payments required under all non-cancelable operating leases at March 31, 2009 are as follows:

Year	
April 1, 2009 to December 31, 2009	\$ 734
2010	810
2011	599
2012	278
2013	103
2014	54
Thereafter	155
Total minimum lease payments	\$ 2,733

In 1982, the Company discovered and thereafter removed a number of buried drums containing unidentified waste material from the Company's site in Slate Hill, New York. The Company thereafter entered into a Consent Decree to evaluate the drum site with the New York Department of Environmental Conservation ("NYDEC") and performed a Remedial Investigation/Feasibility Study that was approved by NYDEC in February 1994. Based on NYDEC requirements, the Company cleaned the area and removed additional soil from the drum burial site, which was completed in 1996. The Company

Edgar Filing: BALCHEM CORP - Form 10-Q

continues to be involved in discussions with NYDEC to evaluate test results and determine what, if any, additional actions will be required on the part of the Company to close out the remediation of this site. Additional actions, if any, would likely require the Company to continue monitoring the site. The cost of such monitoring has been less than \$5 per year for the period 2003 - 2008.

The Company's Verona, Missouri facility, while held by a prior owner, was designated by the EPA as a Superfund site and placed on the National Priorities List in 1983, because of dioxin contamination on portions of the site. Remediation conducted by the prior owner under the oversight of the EPA and the Missouri Department of Natural Resources ("MDNR") included removal of dioxin contaminated soil and equipment, capping of areas of residual contamination in four relatively small areas of the site separate from the manufacturing facilities, and the installation of wells to monitor groundwater and surface water contamination by organic chemicals. No ground water or surface water treatment was required. The Company believes that remediation of the site is complete. In 1998, the EPA certified the work on the contaminated soils to be complete. In February 2000, after the conclusion of two years of monitoring groundwater and surface water, the former owner submitted a draft third party risk assessment report to the EPA and MDNR recommending no further action. The prior owner is awaiting the response of the EPA and MDNR to the draft risk assessment.

While the Company must maintain the integrity of the capped areas in the remediation areas on the site, the prior owner is responsible for completion of any further Superfund remedy. The Company is indemnified by the sellers under its May 2001 asset purchase agreement covering its acquisition of the Verona, Missouri facility for potential liabilities associated with the Superfund site and one of the sellers, in turn, has the benefit of certain contractual indemnification by the prior owner that is implementing the above-described Superfund remedy.

From time to time, the Company is a party to various litigation, claims and assessments. Management believes that the ultimate outcome of such matters will not have a material effect on the Company's consolidated financial position, results of operations, or liquidity.

NOTE 13 - NEW ACCOUNTING PRONOUNCEMENTS

In May 2008, FASB issued SFAS No. 162, "The Hierarchy of Generally Accepted Accounting Principles" ("SFAS 162"). SFAS 162 is intended to improve financial reporting by identifying a consistent framework, or hierarchy, for selecting accounting principles to be used in preparing financial statements that are presented in conformity with U.S. generally accepted accounting principles ("GAAP") for nongovernmental entities. Prior to the issuance of SFAS No. 162, the GAAP hierarchy was defined in the American Institute of Certified Public Accountants' (AICPA) Statement on Auditing Standards (SAS) No. 69, "The Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles." SFAS No. 162 was effective November 15, 2008. The adoption of this statement was not significant to the Company's consolidated financial statements.

In April 2008, FASB issued FSP 142-3, "Determining the Useful Life of Intangible Assets" ("FSP 142-3"). FSP 142-3 amends the factors to be considered in determining the

Edgar Filing: BALCHEM CORP - Form 10-Q

useful life of intangible assets. Its intent is to improve the consistency between the useful life of an intangible asset and the period of expected cash flows used to measure its fair value. FSP 142-3 is effective for fiscal years beginning after December 15, 2008. The adoption of this statement was not significant to the Company's consolidated financial statements.

In March 2008, FASB issued Statement of Financial Accounting Standards No. 161, "Disclosures about Derivative Instruments and Hedging Activities -- an amendment of FASB Statement No. 133" ("SFAS 161"). SFAS 161 requires enhanced disclosures regarding derivatives and hedging activities, including: (a) the manner in which an entity uses derivative instruments; (b) the manner in which derivative instruments and related hedged items are accounted for under Statement of Financial Accounting Standards No. 133, "Accounting for Derivative Instruments and Hedging Activities"; and (c) the effect of derivative instruments and related hedged items on an entity's financial position, financial performance, and cash flows. SFAS 161 is effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008. As SFAS 161 relates specifically to disclosures, the adoption of this statement was not significant to the Company's consolidated financial statements.

In December 2007, FASB issued SFAS No. 141 (revised 2007), "Business Combinations", or SFAS 141R. The purpose of issuing the statement is to replace current guidance in SFAS No. 141 to better represent the economic value of a business combination transaction. The changes to be effected with SFAS 141R from the current guidance include, but are not limited to: (1) acquisition costs will be recognized separately from the acquisition; (2) known contractual contingencies at the time of the acquisition will be considered part of the liabilities acquired measured at their fair value; all other contingencies will be part of the liabilities acquired measured at their fair value only if it is more likely than not that they meet the definition of a liability; (3) contingent consideration based on the outcome of future events will be recognized and measured at the time of the acquisition; (4) business combinations achieved in stages (step acquisitions) will need to recognize the identifiable assets and liabilities, as well as noncontrolling interests, in the acquiree, at the full amounts of their fair values; and (5) a bargain purchase (defined as a business combination in which the total acquisition-date fair value of the identifiable net assets acquired exceeds the fair value of the consideration transferred plus any noncontrolling interest in the acquiree) will require that excess to be recognized as a gain attributable to the acquirer. SFAS 141R is effective for any business combinations that occur after January 1, 2009. The Company will apply SFAS 141R prospectively to all business combinations subsequent to the effective date.

In December 2007, the FASB issued SFAS No. 160, "Noncontrolling Interests in Consolidated Financial Statements -- an amendment of ARB No. 51", or SFAS 160. SFAS 160 was issued to improve the relevance, comparability, and transparency of financial information provided to investors by requiring all entities to report noncontrolling (minority) interests in subsidiaries in the same way, that is, as equity in the consolidated financial statements. Moreover, SFAS 160 eliminates the diversity that currently exists in accounting for transactions between an entity and noncontrolling interests by requiring they be treated as equity transactions. SFAS 160 is effective January 1, 2009. The adoption of this statement was not significant to the Company's consolidated financial statements.

In September 2006, FASB issued SFAS No. 157, "Fair Value Measurements" ("SFAS 157"). SFAS 157 defines fair value, establishes a framework for measuring fair value in accordance with generally accepted accounting principles and expands disclosures about fair value measurements. The Company adopted the provisions of

Edgar Filing: BALCHEM CORP - Form 10-Q

this statement for its financial assets and liabilities as of January 1, 2008 and it did not have a material impact on its financial condition or results of operations. As permitted by FASB Staff Position ("FSP") No. FAS 157-2, "Effective Date of FASB Statement No. 157", the Company elected to defer the adoption of SFAS No. 157 for all nonfinancial assets and nonfinancial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis, until January 1, 2009. Effective January 1, 2009, we adopted the provision for nonfinancial assets and liabilities that are not required or permitted to be measured at fair value on a recurring basis, which include those measured at fair value in impairment testing and those initially measured at fair value in a business combination. The provisions of SFAS No. 157 related to these items did not have a significant impact on the Company's consolidated financial statements. In October 2008, FASB issued FSP No. 157-3, "Determining the Fair Value of a Financial Asset When the Market for That Asset is Not Active." FSP No. 157-3 clarifies the application of SFAS No. 157 in a market that is not active and provides an example of key considerations in determining the fair value of a financial asset when the market for that asset is not active. FSP No. 157-3 was effective on October 10, 2008, including prior periods for which financial statements have not been issued. Revisions resulting from a change in the valuation technique or its application should be accounted for as a change in accounting estimate following the guidance in SFAS No. 154, "Accounting Changes and Error Corrections." The Company adopted FSP No. 157-3 on October 10, 2008 and it did not have a material effect on its consolidated financial statements.

17

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations (All dollar amounts in thousands)

This Report contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, which reflect our expectation or belief concerning future events that involve risks and uncertainties. Our actions and performance could differ materially from what is contemplated by the forward-looking statements contained in this Report. Factors that might cause differences from the forward-looking statements include those referred to or identified in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and other factors that may be identified elsewhere in this Report. Reference should be made to such factors and all forward-looking statements are qualified in their entirety by the above cautionary statements.

Overview

We develop, manufacture, distribute and market specialty performance ingredients and products for the food, nutritional, pharmaceutical, animal health and medical device sterilization industries. Our reportable segments are strategic businesses that offer products and services to different markets. We presently have three reportable segments: Specialty Products; Food, Pharma & Nutrition; and Animal Nutrition & Health.

Specialty Products

Our Specialty Products segment operates in industry as ARC Specialty Products.

Ethylene oxide, at the 100% level, is sold as a sterilant gas, primarily for use in the health care industry. It is used to sterilize a wide range of medical devices because of its versatility and effectiveness in treating hard or soft surfaces, composites, metals, tubing and different types of plastics without

Edgar Filing: BALCHEM CORP - Form 10-Q

negatively impacting the performance of the device being sterilized. Our 100% ethylene oxide product is distributed in uniquely designed, recyclable, double-walled, stainless steel drums to assure compliance with safety, quality and environmental standards as outlined by the U.S. Environmental Protection Agency (the "EPA") and the U.S. Department of Transportation. Our inventory of these specially built drums, along with our two filling facilities, represents a significant capital investment. Contract sterilizers, medical device manufacturers, and medical gas distributors are our principal customers for this product. In addition, we also sell single use canisters with 100% ethylene oxide for use in medical device sterilization. As a fumigant, ethylene oxide blends are highly effective in killing bacteria, fungi, and insects in spices and other seasoning materials.

We also sell propylene oxide principally to customers seeking smaller (as opposed to bulk) quantities and whose requirements include timely delivery and safe handling. Propylene oxide uses can include fumigation in spice treatment, various chemical synthesis applications, to make paints more durable, and for manufacturing specialty starches and textile coatings.

Food, Pharma & Nutrition -----

The Food, Pharma & Nutrition ("FP&N") segment provides microencapsulation, granulation and agglomeration solutions to a variety of applications in food,

18

pharmaceutical and nutritional ingredients to enhance performance of nutritional fortification, processing, mixing, and packaging applications and shelf-life. Major product applications are baked goods, refrigerated and frozen dough systems, processed meats, seasoning blends, confections, and nutritional supplements. We also market human grade choline nutrient products through this segment for wellness applications. Choline is recognized to play a key role in the development and structural integrity of brain cell membranes in infants, processing dietary fat, reproductive development and neural functions, such as memory and muscle function. The FP&N portfolio also includes granulated calcium carbonate products, primarily used in, or in conjunction with, novel over-the-counter and prescription pharmaceuticals for the treatment of osteoporosis, gastric disorders and calcium deficiencies in the United States.

Animal Nutrition & Health -----

Our Animal Nutrition & Health ("AN&H") segment provides the animal nutrition market with nutritional products derived from our encapsulation and chelation technologies in addition to basic choline chloride. Commercial sales of REASHURE(R) Choline, an encapsulated choline product, NITROSHURETM, an encapsulated urea supplement, and NIASHURETM, our microencapsulated niacin product for dairy cows, boosts health and milk production in transition and lactating dairy cows, delivering nutrient supplements that survive the rumen and are biologically available, providing required nutritional levels. We also market chelated mineral supplements for use in animal feed throughout the world, as our proprietary chelation technology provides enhanced nutrient absorption for various species of production and companion animals. In October 2008, we introduced the first proven rumen-protected lysine for use in dairy rations, AMINOSHURETM-L, which gives nutritionists and dairy producers a precise and consistent source of rumen-protected lysine. AN&H also manufactures and supplies basic choline chloride, an essential nutrient for animal health, predominantly to the poultry and swine industries. Choline, which is manufactured and sold in both dry and aqueous forms, plays a vital role in the metabolism of fat. Choline deficiency can result in reduced growth and perosis in poultry; fatty liver,

Edgar Filing: BALCHEM CORP - Form 10-Q

kidney necrosis and general poor health condition in swine. Certain derivatives of choline chloride are also manufactured and sold into industrial applications. The AN&H segment also includes the manufacture and sale of methylamines. Methylamines are a primary building block for the manufacture of choline products and are also used in a wide range of industrial applications.

We sell products for all three segments through our own sales force, independent distributors, and sales agents.

19

The following tables summarize consolidated net sales by segment and business segment earnings from operations for the three months ended March 31, 2009 and March 31, 2008:

Business Segment Net Sales:

	Three Months Ended March 31,	
	2009	2008
Specialty Products	\$ 8,794	\$ 8,450
Food, Pharma & Nutrition	8,304	9,289
Animal Nutrition & Health	35,888	39,122
Total	\$ 52,986	\$ 56,861

Business Segment Earnings From Operations:

	Three Months Ended March 31,	
	2009	2008
Specialty Products	\$ 3,387	\$ 2,598
Food, Pharma & Nutrition	959	1,528
Animal Nutrition & Health	4,964	3,278
Total	\$ 9,310	\$ 7,404

20

RESULTS OF OPERATIONS

Three months ended March 31, 2009 compared to three months ended March 31, 2008.

Net Sales

Net sales for the three months ended March 31, 2009 were \$52,986, as compared with \$56,861 for the three months ended March 31, 2008, a decrease of \$3,875 or 6.8%. Net sales for the Specialty Products segment were \$8,794 for the three months ended March 31, 2009, as compared with \$8,450 for the three months ended

Edgar Filing: BALCHEM CORP - Form 10-Q

March 31, 2008, an increase of \$344 or 4.1%. This increase in sales was derived principally from a combination of increases in volume and average selling price of certain ethylene oxide products for medical device sterilization. Net sales for the Food, Pharma & Nutrition segment were \$8,304 for the three months ended March 31, 2009 compared with \$9,289 for the three months ended March 31, 2008, a decrease of \$985 or 10.6%. This result was driven principally by aggressive inventory management by customers along with volume declines in the international food market and human-grade choline and calcium products for the supplement market, all of which have been negatively impacted by the worldwide economic downturn. These declines were partially offset by a favorable product mix sold in the domestic food market, including the launch of choline into new food applications as well as growth in the bakery, tortilla and preservation markets. Also offsetting the declines was increased volumes of Vitashure(R) products for nutritional enhancement. Net sales of \$35,888 were realized for the three months ended March 31, 2009 for the Animal Nutrition & Health segment, as compared with \$39,122 for the prior year comparable quarter, a decrease of \$3,234 or 8.3%. Feed and industrial grade choline product sales and derivatives decreased 10.3%, or \$3,464 over the prior year quarter, principally from a decline in volume sold into the well-publicized soft poultry industry, including lower international sales largely related to the strengthening of the U.S dollar in 2009 versus a weakening dollar in 2008. Sales of industrial derivatives (both choline and methylamines) were impacted by softness in the industrial sector, principally caused by the general economic downturn. Sales of our specialty animal nutrition and health products, targeted for ruminant production animals and companion animals, increased 4.1% or \$230 over the prior year comparable quarter primarily due to a favorable sales mix, including new sales generated from AminoShureTM-L, the Company's rumen protected lysine product.

Operating Expenses

Operating expenses for the three months ended March 31, 2009 were \$6,988, as compared to \$6,079 for the three months ended March 31, 2008, an increase of \$909 or 15.0%. This increase was due primarily to increased payroll expenses along with an increase to some accounts receivable reserves for international accounts. Operating expenses were 13.2% of sales or 2.5 percentage points more than the operating expenses as a percent of sales incurred in last year's comparable quarter. During the three months ended March 31, 2009 and 2008, the Company spent \$808 and \$782 respectively, on research and development programs, substantially all of which pertained to the Company's Food, Pharma & Nutrition and Animal Nutrition & Health segments.

21

Business Segment Earnings From Operations

Earnings from operations for the three months ended March 31, 2009 increased to \$9,310 compared to \$7,404 for the three months ended March 31, 2008, an increase of \$1,906 or 25.7%. This increase was primarily driven by cost reductions of certain petro-chemical raw materials over the prior year comparable quarter and increases in average selling prices. Earnings from operations as a percentage of sales ("operating margin") for the three months ended March 31, 2009 increased to 17.6% compared to 13.0% for the three months ended March 31, 2008, principally a result of product mix and the aforementioned cost reduction of certain petro-chemical raw materials. The Company is continuing to focus on implementing productivity improvements and, most importantly, growth through new product development. Earnings from operations for the Specialty Products segment were \$3,387, an increase of \$789 or 30.4%, primarily due to reductions in the cost of certain petro-chemical raw materials and increases in average selling prices. Earnings from operations for Food, Pharma & Nutrition were \$959, a

Edgar Filing: BALCHEM CORP - Form 10-Q

decrease of \$569 or 37.2%, due largely to the aforementioned aggressive inventory management by customers and volume declines in the international food market, human-grade choline and calcium products for the supplement market. Earnings from operations for Animal Nutrition & Health increased by \$1,686 to \$4,964, a 51.4% increase from the prior comparable quarter, resulting principally from reductions in the cost of certain petro-chemical raw materials and increases in average selling prices.

Other Expenses (Income)

Interest income for the three months ended March 31, 2009 totaled \$10 as compared to \$25 for the three months ended March 31, 2008. Interest expense was \$74 for the three months ended March 31, 2009 compared to \$323 for the three months ended March 31, 2008. This decrease is primarily attributable to the decrease in average current and long-term debt resulting from both normal recurring principal payments as well as accelerated payments of the Term Loan (as defined below in the Financing Activities section of Liquidity and Capital Resources). Other expense of \$80 for the three months ended March 31, 2009 is primarily the result of unfavorable fluctuations in foreign currency exchange rates between the U.S. dollar (the reporting currency) and functional foreign currencies.

Income Tax Expense

The Company's effective tax rate for the three months ended March 31, 2009 and 2008 was 33.5% and 35.5% respectively. This decrease in the effective tax rate is primarily attributable to a change in apportionment factors relating to state income taxes.

Net Earnings

Primarily as a result of the above-noted cost reductions of certain petro-chemical raw materials, increases in average selling prices and the favorable product mix, net earnings were \$6,098 for the three months ended March 31, 2009, as compared with \$4,641 for the three months ended March 31, 2008, an increase of 31.4%.

22

FINANCIAL CONDITION

LIQUIDITY AND CAPITAL RESOURCES

Contractual Obligations

The Company's contractual obligations and commitments principally include obligations associated with future minimum non-cancelable operating lease obligations (including for the headquarters office space entered into in 2002), long-term debt obligations and purchase obligations principally related to open purchase orders for inventory not yet received or recorded on our balance sheet.

The Company knows of no current or pending demands on, or commitments for, its liquid assets that will materially affect its liquidity.

Edgar Filing: BALCHEM CORP - Form 10-Q

During the three months ended March 31, 2009, there were no material changes outside the ordinary course of business in the specified contractual obligations set forth in our Annual Report on Form 10-K for the year ended December 31, 2008. The Company expects its operations to continue generating sufficient cash flow to fund working capital requirements and necessary capital investments. The Company is actively pursuing additional acquisition candidates. The Company could seek additional bank loans or access to financial markets to fund such acquisitions, its operations, working capital, necessary capital investments or other cash requirements should it deem it necessary to do so.

Cash

Cash and cash equivalents increased to \$18,553 at March 31, 2009 from \$3,422 at December 31, 2008 primarily resulting from the information detailed below. Working capital amounted to \$38,319 at March 31, 2009 as compared to \$29,566 at December 31, 2008, an increase of \$8,753.

Operating Activities

Cash flows from operating activities provided \$18,501 for the three months ended March 31, 2009 compared to \$7,232 for the three months ended March 31, 2008. The increase in cash flows from operating activities was primarily due to an increase in net earnings, lower accounts receivable, a decrease in inventories and prepaid expenses, and higher income taxes.

23

Investing Activities

Capital expenditures were \$594 for the three months ended March 31, 2009 compared to \$1,236 for the three months ended March 31, 2008.

Financing Activities

The Company has an approved stock repurchase program. The total authorization under this program is 2,508,692 shares. Since the inception of the program, a total of 1,307,867 shares have been purchased, none of which remained in treasury at March 31, 2009 or 2008. During the three months ended March 31, 2009, no additional shares have been purchased. The Company intends to acquire shares from time to time at prevailing market prices if and to the extent it deems it advisable to do so based on its assessment of corporate cash flow, market conditions and other factors.

On April 30, 2007, the Company, and its principal bank entered into a Loan Agreement (the "European Loan Agreement") providing for an unsecured term loan of (euro)7,500, translated to \$9,906 as of March 31, 2009 (the "European Term Loan"), the proceeds of which were used to fund the 2007 Akzo Nobel Acquisition (described in Note 5 to the Consolidated Financial Statements of the Company's Form 10-K as of December 31, 2008) and initial working capital requirements. The European Term Loan is payable in equal monthly installments of principal, each equal to 1/84th of the principal of the European Term Loan, together with accrued interest, with remaining principal and interest payable at maturity. The European Term Loan has a maturity date of May 1, 2010 and is subject to a monthly interest rate equal to EURIBOR plus 1%. At March 31, 2009, this interest rate was 2.54%. At March 31, 2009, the European Term Loan had an outstanding balance of (euro)5,536, translated to \$7,312. The European Loan Agreement also

Edgar Filing: BALCHEM CORP - Form 10-Q

provides for a short-term revolving credit facility of (euro)3,000, translated to \$3,962 as of March 31, 2009 (the "European Revolving Facility"). The European Revolving Facility has been renewed for a period of one year as of May 1, 2009. The current European Revolving Facility is subject to an amended monthly interest rate equal to EURIBOR plus 1.45%, and accrued interest is payable monthly. The Company has drawn down (euro)1,450, or \$1,915 as translated at March 31, 2009, of the European Revolving Facility as of March 31, 2009.

On March 16, 2007, the Company and its principal bank entered into a Loan Agreement (the "Loan Agreement") providing for an unsecured term loan of \$29,000 (the "Term Loan"), the proceeds of which were used to fund the 2007 Chinook Acquisition (described in Note 5 to the Consolidated Financial Statements of the Company's Form 10-K as of December 31, 2008). During the quarter ended March 31, 2009, the Company prepaid \$867, the remaining balance of the Term Loan. The Loan Agreement also provides for a short-term revolving credit facility of \$6,000 (the "Revolving Facility"). The Revolving Facility is subject to a monthly interest rate equal to LIBOR plus 1%, and accrued interest is payable monthly. No amounts are outstanding on the Revolving Facility as of the date hereof. The Revolving Facility has a maturity date of May 31, 2010. Management believes that such facility will be renewed in the normal course of business.

Proceeds from stock options exercised totaled \$701 and \$413 for the three months ended March 31, 2009 and 2008, respectively. Dividend payments were \$2,007 and \$1,975 for the three months ended March 31, 2009 and 2008, respectively.

24

Other Matters Impacting Liquidity

The Company currently provides postretirement benefits in the form of a retirement medical plan under a collective bargaining agreement covering eligible retired employees of its Verona, Missouri facility. The amount recorded on the Company's balance sheet as of March 31, 2009 for this obligation is \$833. The postretirement plan is not funded. Historical cash payments made under such plan have approximated \$50 per year.

Critical Accounting Policies

There were no changes to the Company's Critical Accounting Policies, as described in its December 31, 2008 Annual Report on Form 10-K, during the three months ended March 31, 2009.

Related Party Transactions

The Company was not engaged in related party transactions during the three months ended March 31, 2009.

25

Item 3. Quantitative and Qualitative Disclosures about Market Risk

Cash and cash equivalents are invested primarily in money market accounts. The

Edgar Filing: BALCHEM CORP - Form 10-Q

money market funds in which the Company invests are participants in the United States Treasury Department's Temporary Guarantee Program for Money Market Funds. This program provides coverage for amounts held in money market funds as of the close of business on September 19, 2008. The Company has no derivative financial instruments or derivative commodity instruments, nor does the Company have any financial instruments entered into for trading or hedging purposes. As of March 31, 2009, the Company's borrowings were under a bank term loan bearing interest at EURIBOR plus 1.00% and a revolving line of credit bearing interest at EURIBOR plus 1.25%. A 100 basis point increase or decrease in interest rates, applied to the Company's borrowings at March 31, 2009, would result in an increase or decrease in annual interest expense and a corresponding reduction or increase in cash flow of approximately \$92. The Company is exposed to market risks for changes in foreign currency rates and has exposure to commodity price risks, including prices of our primary raw materials. Our objective is to seek a reduction in the potential negative earnings impact of changes in foreign exchange rates and raw material pricing arising in our business activities. The Company manages these financial exposures, where possible, through pricing and operational means. Our practices may change as economic conditions change.

26

Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Pursuant to the requirements of the Sarbanes-Oxley Act of 2002, the Company's management, under the supervision and with the participation of the Company's Chief Executive Officer and Chief Financial Officer, has evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of the Company's disclosure controls and procedures (including its internal controls and procedures.)

Based upon management's evaluation, the Chief Executive Officer and the Chief Financial Officer have concluded that, as of the end of such period, the Company's disclosure controls and procedures were effective in identifying the information required to be disclosed in the Company's periodic reports filed with the Securities and Exchange Commission ("SEC"), including this Quarterly Report on Form 10-Q, and ensuring that such information is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms.

(b) Changes in Internal Controls

During the most recent fiscal quarter, there has been no significant change in the Company's internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

27

Part II. Other Information

Item 1A. Risk Factors

Edgar Filing: BALCHEM CORP - Form 10-Q

There have been no material changes in the Risk Factors identified in the Company's Annual Report on Form 10-K for the year ended December 31, 2008.

Item 4. Submission of Matters to a Vote of Security Holders.

None.

Item 6. Exhibits

Exhibit 31.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(a).

Exhibit 31.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(a).

Exhibit 32.1 Certification of Chief Executive Officer pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.

Exhibit 32.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

BALCHEM CORPORATION

By: /s/ Dino A. Rossi

Dino A. Rossi, Chairman, President and
Chief Executive Officer

Date: May 8, 2009

28

Exhibit Index

Exhibit No. -----	Description -----
Exhibit 31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a).
Exhibit 31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a).
Exhibit 32.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.

Edgar Filing: BALCHEM CORP - Form 10-Q

Exhibit 32.2 Certification of Chief Financial Officer pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.